Intravenous (IV) glutathione , often used in clinical settings or for cosmetic purposes like skin lightening, is more potent but carries a higher risk of side effects
Not for medicinal use
Conclusions and perspectives Despite all the controversy in this space, the general consensus is that irAEs are not a pre-requisite for ICI benefit but rather a positive heralding sign of clinical benefit
Critically, patients who discontinued treatment saw fat return to baseline within 26 weeks, confirming the effect requires continued use to maintain
Category 1 status allows licensed U.S
Supplementing with glutathione IV therapy may: Improve symptoms of several conditions, including autoimmune disorders, Parkinsons disease, and diabetes Improve insulin resistance that has declined due to age Research suggests that glutathione deficiency might be linked to COVID-19, with lower levels potentially increasing the risk of severe symptoms